PulseSight Therapeutics, a Paris, France-based ophthalmology biotech company, raised an undisclosed amount in Seed funding.

总部位于法国巴黎的眼科生物技术公司PulseSight Therapeutics筹集了一笔未披露的种子资金。

The round was led by Pureos Bioventures and ND Capital, with participation from Korea Investment Partners.

本轮谈判由Pureos Bioventures和ND Capital牵头，韩国投资合作伙伴参与。

The company intends to use the funds to expand operations and its R&D sector.

该公司打算将资金用于扩大运营和研发部门。

Led by CEO Judith Greciet, PulseSight Therapeutics is an ophthalmology drug development company developing non-viral gene therapies with minimally-invasive delivery technology designed to address the unmet need for treatments against severe retinal diseases leading to blindness, with a focus on age-related macular degeneration (AMD) including wet AMD and geographic atrophy (GA) in late-stage dry AMD..

PulseSight Therapeutics由首席执行官朱迪思·格雷西特（JudithGreciet）领导，是一家眼科药物开发公司，开发非病毒基因疗法，采用微创递送技术，旨在解决严重视网膜疾病导致失明的治疗需求未得到满足，重点关注与年龄有关的黄斑变性（AMD），包括湿性AMD和地理萎缩（GA）晚期干性AMD。。

Lead program, PST-809, in wet AMD and a second program, PST-611, in dry AMD/GA are at the very late stage of preclinical IND enabling studies and build on over a decade of development of non-viral gene therapies. Already validated in the clinic for safety and delivery, this non-viral delivery platform delivers DNA plasmids encoding therapeutic proteins into the ciliary muscle to safely and sustainably treat major eye diseases.

湿性AMD的主要计划PST-809和干性AMD/GA的第二个计划PST-611处于临床前IND研究的后期阶段，并建立在非病毒基因疗法十多年的发展基础上。这种非病毒传递平台已经在临床上进行了安全性和传递性验证，它将编码治疗性蛋白质的DNA质粒传递到睫状肌中，以安全和可持续地治疗主要的眼部疾病。

The company’s technology and therapeutic applications are covered by an IP portfolio of 11 patent families, with 90 granted patents..

该公司的技术和治疗应用涵盖了11个专利家族的知识产权组合，拥有90项授权专利。

Commenting on the news, Judith Greciet said: “I am excited to join the company with a validated and highly differentiating delivery platform and two non-viral gene therapy programs at late preclinical stage. Our proprietary non-viral gene therapy approach provides unique features in terms of efficacy, safety and durability of effect and I am thrilled to have the opportunity to work with PulseSight Therapeutics’ highly experienced team and board to build the company’s future.”.

评论新闻，朱迪思·格雷西特说：“我很高兴能在临床前后期加入该公司，拥有一个经过验证且极具特色的交付平台和两个非病毒基因治疗计划。我们专有的非病毒基因治疗方法在疗效，安全性和持久性方面提供了独特的功能，我很高兴有机会与PulseSight Therapeutics经验丰富的团队a合作董事会将打造公司的未来。”